PreveCeutical Medical Inc. focuses on developing preventive and curative therapies using organic and nature-identical products. The company faces significant concerns, including a very low current ratio of 0.03, indicating liquidity issues, and a negative return on assets of -347.0%, suggesting inefficiency in asset utilization. Additionally, the stock has dropped 25% today, reflecting potential investor skepticism. While the biotechnology sector holds promise, PreveCeutical's financial health raises red flags that warrant caution for potential investors.
Loading financial metrics...
Company has $4K in cash but burned $211K last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Company posted a loss of $-2.6M over the last year, representing Infinity% of revenue.
Debt of $4.6M is 1068.3x the company's cash position of $4K.
Operating cash flow has been negative for 3 consecutive quarters, burning $843K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)